ppack ii (Millipore)
Millipore is a verified supplier 
90
Structured Review
Millipore
ppack ii
Ppack Ii, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppack+ii/ppack+ii/us11760745-201-1-3
Average 90 stars, based on 1 article reviews
Ppack Ii, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppack+ii/ppack+ii/us11760745-201-1-3
Average 90 stars, based on 1 article reviews
ppack ii - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Activity Assay:Article Title: Disclosing the involvement of proteases in an eczema murine animal model: Perspectives for protease inhibitor-based therapies. Article Snippet: Eczema is a skin condition characterized by itchy and inflammatory patches.. The accumulation of neutrophils and the imbalance between enzymes and their inhibitors appears to be related to this condition.. We proposed a neutrophil elastase (NE)-based eczema model in mice in order to verify histopathological features as well as the expression and activity of proteases and inhibitors. Concentration Assay:Article Title: Disclosing the involvement of proteases in an eczema murine animal model: Perspectives for protease inhibitor-based therapies. Article Snippet: Eczema is a skin condition characterized by itchy and inflammatory patches.. The accumulation of neutrophils and the imbalance between enzymes and their inhibitors appears to be related to this condition.. We proposed a neutrophil elastase (NE)-based eczema model in mice in order to verify histopathological features as well as the expression and activity of proteases and inhibitors. Article Title: Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors Article Snippet: Pharmacological Activity The activity of the compounds of the invention may be demonstrated using the following assay: Biological Methods The ability of compounds of formula (I) to inhibit plasma kallikrein (PKK), Factor Xlla (FXIIa), Factor Xla (FXIa), Factor Xa (FXa), Factor Ila (alpha-thrombin; FIIa), plasmin, trypsin, tissue kallikrein 1 (TK1), Factor VIIa (FVIIa), or FVIIa complexed with Tissue Factor, phospholipids and CaCl2 (FVIIa/TF/PL/CaCl2) was determined using the following biochemical assays in assay buffer (100 mM Tris, 150 mM NaCL, adjusted to a pH of 7.8 with HCl, and containing 0.1% (w/v) BSA and 0.05% (v/v) Tween20) in the presence of 1% (v/v) DMSO: EVALUATION OF THE INHIBITION OF PKK USING AN ENDPOINT ASSAY Human PKK (0.01 U/mL; Enzyme Research Laboratories) or rat PKK (0.625 nM; produced in-house) was incubated for 1 h at room temperature with 0.10 μM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295 from Bachem) and various concentrations of the test compound in assay buffer. .. Subsequently, Article Title: Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors Article Snippet: Pharmacological Activity The activity of the compounds of the invention may be demonstrated using the following assays: Biological Methods The ability of compounds of Formula I to inhibit plasma kallikrein (KLKB1), Factor XIIa (FXIIa), Factor XIa (FXIa), Factor Xa (FXa), Factor IIa (alpha-thrombin; FIIa), plasmin, trypsin, tissue kallikrein 1 (KLK1), Factor VIIa (FVIIa), or FVIIa complexed with Tissue Factor, phospholipids and CaCl2 (FVIIa/TF/PL/CaCl2) was determined using the following biochemical assays in assay buffer (100 mM Tris, 150 mM NaCL, adjusted to a pH of 7.8 with HCl, and containing 0.1% (w/v) BSA and 0.05% (v/v) Tween20) in the presence of 1% (v/v) DMSO: Evaluation of the Inhibition of KLKB1 Using an Endpoint Assay Human KLKB1 (0.01 U/mL; Enzyme Research Laboratories) or rat KLKB1 (0.625 nM; produced in-house) was incubated for 1 hr at Room Temperature with 0.10 μM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295 from Bachem) and various concentrations of the test compound in assay buffer. .. Subsequently, Article Title: Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors Article Snippet: According to another embodiment, the invention relates to one or more of the following intermediates Pharmacological Activity The activity of the compounds of the invention may be demonstrated using the following assays: Biological Methods The ability of compounds of formula (I) to inhibit plasma kallikrein (PKK), Factor XIIa (FXIIa), Factor XIa (FXIa), Factor Xa (FXa), Factor IIa (alpha-thrombin; FIIa), plasmin, trypsin, tissue kallikrein 1 (TK1), Factor Vila (FVIIa), or FVIIa complexed with Tissue Factor, phospholipids and CaCl2 (FVIIa/TF/PL/CaCl2) is determined using the following biochemical assays in assay buffer (100 mM Tris, 150 mM NaCL, adjusted to a pH of 7.8 with HCl, and containing 0.1% (w/v) BSA and 0.05% (v/v) Tween20) in the presence of 1% (v/v) DMSO: Evaluation of the Inhibition of PKK Using an Endpoint Assay Human PKK (0.01 U/mL; Enzyme Research Laboratories) or rat PKK (0.625 nM; produced in-house) is incubated for 1 h at room temperature with 0.10 μM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295 from Bachem) and various concentrations of the test compound in assay buffer. .. Subsequently, Incubation:Article Title: Disclosing the involvement of proteases in an eczema murine animal model: Perspectives for protease inhibitor-based therapies. Article Snippet: Eczema is a skin condition characterized by itchy and inflammatory patches.. The accumulation of neutrophils and the imbalance between enzymes and their inhibitors appears to be related to this condition.. We proposed a neutrophil elastase (NE)-based eczema model in mice in order to verify histopathological features as well as the expression and activity of proteases and inhibitors. Protease Inhibitor:Article Title: Disclosing the involvement of proteases in an eczema murine animal model: Perspectives for protease inhibitor-based therapies. Article Snippet: Eczema is a skin condition characterized by itchy and inflammatory patches.. The accumulation of neutrophils and the imbalance between enzymes and their inhibitors appears to be related to this condition.. We proposed a neutrophil elastase (NE)-based eczema model in mice in order to verify histopathological features as well as the expression and activity of proteases and inhibitors. Article Title: Method, composition and device for sampling natriuretic peptides in a biological fluid Article Snippet: An example is BD P100 v1.1 blood collection vacuum tubes (Becton, Dickinson, and Company catalog no. 8013142). .. Protease inhibitors like PPACK I, Fluorescence:Article Title: Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors Article Snippet: Pharmacological Activity The activity of the compounds of the invention may be demonstrated using the following assay: Biological Methods The ability of compounds of formula (I) to inhibit plasma kallikrein (PKK), Factor Xlla (FXIIa), Factor Xla (FXIa), Factor Xa (FXa), Factor Ila (alpha-thrombin; FIIa), plasmin, trypsin, tissue kallikrein 1 (TK1), Factor VIIa (FVIIa), or FVIIa complexed with Tissue Factor, phospholipids and CaCl2 (FVIIa/TF/PL/CaCl2) was determined using the following biochemical assays in assay buffer (100 mM Tris, 150 mM NaCL, adjusted to a pH of 7.8 with HCl, and containing 0.1% (w/v) BSA and 0.05% (v/v) Tween20) in the presence of 1% (v/v) DMSO: EVALUATION OF THE INHIBITION OF PKK USING AN ENDPOINT ASSAY Human PKK (0.01 U/mL; Enzyme Research Laboratories) or rat PKK (0.625 nM; produced in-house) was incubated for 1 h at room temperature with 0.10 μM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295 from Bachem) and various concentrations of the test compound in assay buffer. .. Subsequently, Article Title: Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors Article Snippet: Pharmacological Activity The activity of the compounds of the invention may be demonstrated using the following assays: Biological Methods The ability of compounds of Formula I to inhibit plasma kallikrein (KLKB1), Factor XIIa (FXIIa), Factor XIa (FXIa), Factor Xa (FXa), Factor IIa (alpha-thrombin; FIIa), plasmin, trypsin, tissue kallikrein 1 (KLK1), Factor VIIa (FVIIa), or FVIIa complexed with Tissue Factor, phospholipids and CaCl2 (FVIIa/TF/PL/CaCl2) was determined using the following biochemical assays in assay buffer (100 mM Tris, 150 mM NaCL, adjusted to a pH of 7.8 with HCl, and containing 0.1% (w/v) BSA and 0.05% (v/v) Tween20) in the presence of 1% (v/v) DMSO: Evaluation of the Inhibition of KLKB1 Using an Endpoint Assay Human KLKB1 (0.01 U/mL; Enzyme Research Laboratories) or rat KLKB1 (0.625 nM; produced in-house) was incubated for 1 hr at Room Temperature with 0.10 μM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295 from Bachem) and various concentrations of the test compound in assay buffer. .. Subsequently, Article Title: Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors Article Snippet: According to another embodiment, the invention relates to one or more of the following intermediates Pharmacological Activity The activity of the compounds of the invention may be demonstrated using the following assays: Biological Methods The ability of compounds of formula (I) to inhibit plasma kallikrein (PKK), Factor XIIa (FXIIa), Factor XIa (FXIa), Factor Xa (FXa), Factor IIa (alpha-thrombin; FIIa), plasmin, trypsin, tissue kallikrein 1 (TK1), Factor Vila (FVIIa), or FVIIa complexed with Tissue Factor, phospholipids and CaCl2 (FVIIa/TF/PL/CaCl2) is determined using the following biochemical assays in assay buffer (100 mM Tris, 150 mM NaCL, adjusted to a pH of 7.8 with HCl, and containing 0.1% (w/v) BSA and 0.05% (v/v) Tween20) in the presence of 1% (v/v) DMSO: Evaluation of the Inhibition of PKK Using an Endpoint Assay Human PKK (0.01 U/mL; Enzyme Research Laboratories) or rat PKK (0.625 nM; produced in-house) is incubated for 1 h at room temperature with 0.10 μM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295 from Bachem) and various concentrations of the test compound in assay buffer. .. Subsequently, Inhibition:Article Title: Method, composition and device for sampling natriuretic peptides in a biological fluid Article Snippet: An example is BD P100 v1.1 blood collection vacuum tubes (Becton, Dickinson, and Company catalog no. 8013142). .. Protease inhibitors like PPACK I, other:Article Title: Detection by ELISA of C-terminal proBNP in plasma from cats with cardiomyopathy. Article Snippet: The B-type natriuretic peptide prohormone (proBNP) is enzymatically cleaved into an inactive N-terminal peptide and a biologically active C-terminal peptide with many beneficial cardiorenal effects.. The purpose of this study was to develop and test in cats with cardiomyopathy an immunoassay to quantify the concentrations of C-terminal proBNP in feline plasma.. An anti-canine proBNP monoclonal antibody (UI-1021) was shown to have adequate binding affinity to proBNP 80–106 for use in a solid-phase immunoassay, and by epitope mapping to bind within positions 84–87 of feline proBNP. |